Showing 3731-3740 of 7512 results for "".
- New App-controlled Device May Help Quickly Identify Infected Woundshttps://practicaldermatology.com/news/new-app-controlled-device-may-help-quickly-identify-infected-wounds/2461959/A new app-controlled device may allow doctors to spot infected wounds faster. The scientists developed a device called the Swift Ray 1 which can be attached to a smartphone and connected to the Swift Skin and Wound software. It can take medical-grade photographs, inf
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the&
- New Platform May Help Determine Which Melanoma Patients Will Respond to Immunotherapyhttps://practicaldermatology.com/news/new-platform-may-help-determine-which-melanoma-patients-will-respond-to-immunotherapy/2461949/A new approach that integrates a minimally invasive, painless microneedle platform may help monitor protein biomarkers in responses to a combination immunotherapy against melanoma. The platform is capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers o
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- Angina Drug Ranolazine Improves the Efficacy of Current Treatments for Melanoma in Mouse Modelshttps://practicaldermatology.com/news/angina-drug-ranolazine-improves-the-efficacy-of-current-treatments-for-melanoma-in-mouse-models/2461926/The heart drug ranolazine may improve the efficacy of current therapies for melanoma in mouse models of this disease, according to research out of Navarrabiomed Biomedical Research Center, the Institute of Neurosciences CSIC-UMH, and IRB Barcelona. The development of future clinical tri
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- Electrical Signals Between Skin Cells May Influence Melanoma Initiationhttps://practicaldermatology.com/news/electrical-signals-between-skin-cells-may-influence-melanoma-initiation/2461919/The transfer of a neurotransmitter from melanocytes to keratinocytes alters electrical activity and may promote melanoma initiation in preclinical models, according to results published in
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot